Everstone Capital, the private equity arm of Mumbai-based Mumbai-based Everstone Group, is considering selling its Asian healthcare platform Everlife for as much as $1 billion, according to a report by Bloomberg.
Everstone Capital, the private equity arm of Mumbai-based Mumbai-based Everstone Group, is considering selling its Asian healthcare platform Everlife for as much as $1 billion, according to a report by Bloomberg.
The report cites unnamed sources as revealing that the buyout firm has asked investment banks to submit proposals for the acquisition of the Singapore-headquartered firm with an expected valuation of between $500 million and $1 billion.
Several healthcare industry companies and private equity firms have reportedly shown preliminary interest in a deal although at this stage there is no guarantee that Everstone will proceed with a sale.
According to its company website, is a supplier of diagnostic screening and testing products to clinical laboratories and hospitals, and also provides products for research in biological sciences for academia and research laboratories, plus lab instruments for industries the oil and gas industries.
